SCHEMBL4945191

SCHEMBL4945191

O=S(=O)(O)Cc1cc(-c2cccc(Cl)c2)no1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.67
SMN1; SMN2 Q16637 5/20 0.54
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
HTT P42858 2/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 4/20 0.49
CYP1A2 P05177 3/20 0.48
CYP2C19 P33261 3/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
GAA P10253 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
ALPG P10696 1/20 0.48
ALDH1A1 P00352 1/20 0.45
MMP2 P08253 1/20 0.45
MMP3 P08254 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1544352 0.83 NOTUM (0.72) NOTUMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL22481605 0.81 NOTUM (0.74) NOTUMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL27788409 0.81 NOTUM (0.65) NOTUMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL5744065 0.81 NOTUM (0.68) NOTUMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL22481505 0.80 NOTUM (0.72) NOTUMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL2906394 0.80 NOTUM (1.00) NOTUMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL1545102 0.80 NOTUM (0.59) NOTUMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL27422829 0.78 POLB (0.57) NOTUMSMN1; SMN2NPC1RAB9AHTT
SCHEMBL6408613 0.74 NOTUM (0.55) NOTUMSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL9209121 0.74 NOTUM (0.63) NOTUMSMN1; SMN2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015234-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015234-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS GRM5, GRIK5, GRM2 NOTUM 1681/4885SMN1; SMN2 1409/4885NPC1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.